Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA grants orphan drug designation for MAX-40279 for the treatment of AML

April 5, 2018

PELP-1 mediates adverse response to endocrine therapy for ER-positive breast cancer

April 5, 2018

Conatus reports topline results from phase IIb POLT-HCV-SVR study of emricasan

April 5, 2018

Omigapil completes first clinical trial in patients with congenital muscular dystrophy

April 5, 2018

BB100 licenses MAbs targeting E. coli from Arsanis

April 5, 2018

Boehringer Ingelheim and OSE sign collaboration and license agreement for OSE-172

April 5, 2018

Q-State Biosciences enters drug discovery collaboration with Vertex

April 5, 2018

PLA2-R is a potential diagnostic marker of salivary gland tumors

April 5, 2018

Roche acquires Inception neuroscience program from Versant Ventures

April 5, 2018

Phase III REACH-2 study of Cyramza meets primary endpoint

April 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...